| Active Not Recruiting | Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Mul Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy | Phase 3 | 2023-06-27 |
| Completed | Phase 4 COPD and Suboptimal Inspiratory Flow Rate Chronic Obstructive Pulmonary Disease | Phase 4 | 2022-01-07 |
| Completed | TD-0903 Pharmacokinetics Study in Healthy Participants With Supplemental Oxygenation Acute Lung Injury (ALI) Due to Coronavirus Disease-2019 (COVID-19) | Phase 1 | 2021-10-13 |
| Completed | Comparison of Viral Particle Dispersion Following Administration of an MDI or Nebulizer in Subjects With COVID COVID-19 | — | 2021-05-04 |
| Completed | Thorough QT Study to Evaluate Ampreloxetine in Healthy Subjects Symptomatic Neurogenic Orthostatic Hypertension, nOH | Phase 1 | 2021-01-18 |
| Completed | Single Dose Bioavailability and Ethnobridging PK Study in Healthy Subjects Intestinal Disorder, Bowel Diseases, Inflammatory | Phase 1 | 2020-10-16 |
| Terminated | TD-1058 First-In-Human Study in Healthy Subjects and Subjects With Idiopathic Pulmonary Fibrosis Idiopathic Pulmonary Fibrosis (IPF) | Phase 1 | 2020-10-15 |
| Terminated | TD-1473 Long-Term Safety (LTS) Ulcerative Colitis (UC) Study Ulcerative Colitis (UC) | Phase 2 / Phase 3 | 2020-07-23 |
| Completed | TD-0903 for ALI Associated With COVID-19 Acute Lung Injury (ALI) Associated With COVID-19, Lung Inflammation Associated With COVID-19 | Phase 2 | 2020-06-24 |
| Completed | First in Human SAD and MAD Study of Inhaled TD-0903, a Potential Treatment for ALI Associated With COVID-19 Acute Lung Injury (ALI) Associated With COVID-19, Inflammatory Lung Conditions Associated With COVID-19 | Phase 1 | 2020-04-23 |
| Completed | Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of TD-9855 Symptomatic Neurogenic Orthostatic Hypertension, nOH | Phase 1 | 2020-01-13 |
| Completed | Effect of Inhaled TD-8236 on Allergen-induced Asthmatic Response Asthma | Phase 2 | 2019-11-06 |
| Terminated | Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Symptomatic Neurogenic Orthostatic Hypotension | Phase 3 | 2019-09-19 |
| Completed | Single and Multiple Ascending Dose, First-in- Human Study in Healthy Subjects Healthy | Phase 1 | 2019-08-08 |
| Terminated | Efficacy & Safety of TD-1473 in Ulcerative Colitis Ulcerative Colitis (UC) | Phase 2 / Phase 3 | 2019-03-11 |
| Terminated | Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Symptomatic Neurogenic Orthostatic Hypotension, MSA, Parkinson's Disease (PD) | Phase 3 | 2019-02-22 |
| Completed | Clinical Effect of Ampreloxetine (TD-9855) for Treating Symptomatic nOH in Subjects With Primary Autonomic Fai Symptomatic Neurogenic Orthostatic Hypotension | Phase 3 | 2019-01-24 |
| Completed | Multiple Dose Ethnobridging PK Study in Healthy Subjects Inflammatory Bowel Diseases, IBD | Phase 1 | 2018-11-27 |
| Terminated | Efficacy and Safety of TD-1473 in Crohn's Disease Crohn's Disease | Phase 2 | 2018-11-19 |
| Completed | Single and Multiple Ascending Dose Study of TD-8236 by Inhalation Asthma | Phase 1 | 2018-11-07 |
| Completed | Food-effect, Drug-Drug Interaction (DDI), and Formulation Bridging Study Inflammatory Bowel Disease | Phase 1 | 2018-06-13 |
| Completed | Drug-Drug Interaction (DDI) Study for TD-9855 Drug Drug Interaction (DDI) | Phase 1 | 2018-02-28 |
| Completed | TD-1473 Absorption, Distribution, Metabolism and Excretion (ADME) Study in Healthy Male Subjects Intestinal Disorders, Bowel Diseases, Inflammatory | Phase 1 | 2018-01-31 |
| Completed | TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH) Neurogenic Orthostatic Hypotension, Multiple System Atrophy (MSA) With Orthostatic Hypotension, Pure Autonomic Failure | Phase 2 | 2017-09-09 |
| Completed | TD-3504 SAD in Healthy Subjects and Subjects With Ulcerative Colitis (UC) Active Mild Ulcerative Colitis, Active Moderate Ulcerative Colitis, Healthy Subjects | Phase 1 | 2017-05-04 |
| Completed | Multiple Ascending Dose Study of TD-1439 in Healthy Adult and Elderly Subjects Healthy Adults, Elderly Subjects | Phase 1 | 2016-11-01 |
| Completed | TD-1473 for Active Ulcerative Colitis (UC) Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe | Phase 1 | 2016-10-03 |
| Completed | Single Ascending Dose Study of TD-1439 in Healthy Subjects Healthy Subjects | Phase 1 | 2016-09-01 |
| Completed | Multiple Ascending Dose Study of TD-0714 in Healthy and Elderly Subjects Healthy Adults, Elderly Subjects | Phase 1 | 2016-03-01 |
| Completed | A Phase 1 (Ph1), Single Dose (SD), GSK961081 Absorption, Distribution, Metabolism, and Excretion (ADME) Study Pulmonary Disease, Chronic Obstructive | Phase 1 | 2016-02-08 |
| Completed | SAD and MAD Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of TD-1473 in Healthy Subjects Healthy | Phase 1 | 2015-12-01 |
| Completed | Single Ascending Dose Study of TD-0714 in Healthy Subjects Healthy | Phase 1 | 2015-11-01 |
| Completed | The Diabetic and Idiopathic Gastroparesis Efficacy, Safety, and Tolerability (DIGEST) Study Gastroparesis | Phase 2 | 2014-12-01 |
| Completed | TD-6450 MAD Study in HCV Infected Subjects Hepatitis C, HCV | Phase 1 | 2014-05-01 |
| Completed | TD-6450 SAD and MAD in Healthy Subjects Hepatitis C | Phase 1 | 2014-02-01 |
| Completed | TD-1607 MAD Study in Healthy Subjects Infections, Bacterial Infections | Phase 1 | 2013-10-01 |
| Completed | TD-9855 Mass Balance Study ADHD, Fibromyalgia | Phase 1 | 2013-10-01 |
| Completed | TD-1607 SAD Study in Healthy Subjects Serious Infections Due to Known or Suspected Gram-positive Pathogens | Phase 1 | 2013-04-01 |
| Completed | Phase 2 Study of Velusetrag in Diabetic or Idiopathic Gastroparesis Gastroparesis | Phase 2 | 2012-12-01 |
| Completed | Phase 2 Study of TD-9855 to Treat Fibromyalgia Fibromyalgia | Phase 2 | 2012-11-01 |
| Completed | TD-1211 IV/Oral Mass Balance Study OIC | Phase 1 | 2012-11-01 |
| Terminated | A Phase 1, Multiple Intravenous Dose Study to Examine Safety, Tolerability, and PK of Intravenous TD-8954, a 5 Gastrointestinal Motility Disorder | Phase 1 | 2012-09-01 |
| Completed | TD-1211 Single-Dose Study in Elderly and Young Healthy Subjects Constipation | Phase 1 | 2012-08-01 |
| Completed | A Fixed-Sequence, Two-Period, Open-Label Drug-Drug Interaction Study to Assess the Effect of an Inhibitor of C Healthy | Phase 1 | 2012-04-01 |
| Completed | A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD) Attention-Deficit/Hyperactivity Disorder, ADHD | Phase 2 | 2011-12-01 |
| Completed | A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of TD-1 Opioid Induced Constipation | Phase 2 | 2011-11-01 |
| Completed | A Study of TD-1211 in Subjects With Opioid-Induced Constipation (OIC) Opioid Induced Constipation | Phase 2 | 2011-10-01 |
| Completed | A Study to Assess the Safety, Tolerability and Clinical Activity of TD-1211 in Patients With Opioid-Induced Co Opioid-induced Constipation (OIC) | Phase 2 | 2011-05-01 |
| Completed | A Multiple Dose Study of TD-1211 in Healthy Volunteers and Patients With Opioid-Induced Constipation Healthy, Opioid-induced Constipation | Phase 1 / Phase 2 | 2010-01-01 |
| Completed | An Investigation Of The Interaction Of GSK961081 With Inhaled Beta-Agonist And Anti-Muscarinic Drugs. Pulmonary Disease, Chronic Obstructive | Phase 2 | 2008-04-01 |
| Completed | A Study to Investigate the Pharmacology of a Dual Pharmacophore in Healthy Volunteers Pulmonary Disease, Chronic Obstructive | Phase 1 | 2008-03-10 |
| Completed | Succinate Salt Version of GSK961081 for Healthy Volunteers Pulmonary Disease, Chronic Obstructive | Phase 1 | 2007-11-29 |
| Completed | TD-1792 in Gram-positive Complicated Skin and Skin Structure Infection Staphylococcal Skin Infection | Phase 2 | 2006-12-01 |
| Completed | Study of GSK961081 in Healthy Volunteer Subjects Pulmonary Disease, Chronic Obstructive | Phase 1 | 2005-11-07 |